List Of Off-label Promotion Pharmaceutical Settlements

List of Off-label Promotion Pharmaceutical Settlements

The pharmaceutical industry is governed by strict regulations to ensure the safety and efficacy of medications. However, there have been instances where pharmaceutical companies have engaged in the promotion of drugs for off-label uses, which refers to the practice of marketing or prescribing medications for an indication, age group, dosage, or route of administration that is not approved by the relevant regulatory bodies such as the Food and Drug Administration (FDA) in the United States. This article provides a detailed list of notable settlements related to off-label promotion by pharmaceutical companies.

Overview

Off-label promotion of pharmaceuticals is a contentious issue within the medical and legal communities. While doctors are allowed to prescribe drugs for off-label uses, pharmaceutical companies are prohibited from marketing their products for any use not specifically approved by the FDA. The settlements listed below involve cases where companies have been found to engage in such prohibited marketing practices, often resulting in significant financial penalties and stringent regulatory oversight measures.

List of Settlements

Pfizer

In 2009, Pfizer agreed to a $2.3 billion settlement, the largest healthcare fraud settlement at that time, for the off-label promotion of four drugs, including the painkiller Bextra. This case highlighted the issue of pharmaceutical companies prioritizing profits over patient safety and regulatory compliance.

GlaxoSmithKline

GlaxoSmithKline (GSK) settled for $3 billion in 2012, after being accused of promoting several drugs, including the antidepressant Paxil and the diabetes medication Avandia, for unapproved uses. This settlement also included allegations of failing to report safety data.

Johnson & Johnson

In 2013, Johnson & Johnson paid more than $2.2 billion to resolve criminal and civil liabilities related to the off-label promotion of the antipsychotic Risperdal, among other drugs. The settlement addressed allegations of kickbacks to physicians and pharmacists to promote the drugs for unapproved uses.

Eli Lilly

Eli Lilly and Company settled for $1.415 billion in 2009 for the off-label promotion of the antipsychotic drug Zyprexa. The settlement included a criminal fine and forfeiture totaling $515 million, one of the largest amounts ever paid by a drug company for a criminal charge.

AbbVie

In 2021, AbbVie and its subsidiary Allergan agreed to pay $24 million to settle allegations of off-label promotion related to the drug Linzess, used for treating irritable bowel syndrome with constipation. This settlement resolved claims of misleading marketing practices.

Regulatory and Ethical Considerations

The settlements underscore the importance of adhering to regulatory guidelines and ethical standards in the promotion and marketing of pharmaceuticals. Off-label promotion undermines the regulatory framework designed to protect patient safety and erodes public trust in the pharmaceutical industry and healthcare providers.

Conclusion

The list of settlements related to off-label promotion of pharmaceuticals highlights the ongoing challenges in ensuring ethical marketing practices within the pharmaceutical industry. These cases serve as a reminder of the critical role of regulatory bodies in monitoring and enforcing compliance to safeguard public health.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian